1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. Everest Medicines Limited
  6. News
  7. Summary
    1952   KYG3224E1061

EVEREST MEDICINES LIMITED

(1952)
  Report
Delayed Hong Kong Stock Exchange  -  05/19 04:08:33 am EDT
21.80 HKD   -2.90%
04/07Everest Medicines to Form Vaccine JV With China Resources Pharmaceutical
MT
04/06Everest Medicines Announces that Topline Results from Chinese Subpopulation Consistent With Global Phase 3 NefIgArd Study Part A Analysis
CI
04/05Everest Medicines Announces that Topline Results from Chinese Subpopulation Consistent With Global Phase 3 NefIgArd Study Part A Analysis
PR
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Everest Medicines and Providence Therapeutics Jointly Announce Vaccine Development Strategy to Address Omicron (B.1.1.529) SARS-CoV-2 Variant

11/30/2021 | 07:01pm EDT

Everest Medicines and Providence Therapeutics (Providence) jointly announced that the companies have started working on a new version of COVID-19 vaccine specifically targeting the new Omicron variant. Scientists from the two companies have analyzed the sequence of the SARS-CoV-2 Omicron variant, selected viral sequences, and designed plasmid clones. The company expected the new Omicron SARS-CoV-2 variant vaccines can be advanced into clinical testing in less than 100 days.


© S&P Capital IQ 2021
All news about EVEREST MEDICINES LIMITED
04/07Everest Medicines to Form Vaccine JV With China Resources Pharmaceutical
MT
04/06Everest Medicines Announces that Topline Results from Chinese Subpopulation Consistent ..
CI
04/05Everest Medicines Announces that Topline Results from Chinese Subpopulation Consistent ..
PR
03/31Everest Medicines Submits New Drug Application in Hong Kong for Sacituzumab Govitecan
CI
03/28Everest Medicines Narrows Loss as General, Administrative Expenses Fall in 2021
MT
03/28TRANSCRIPT : Everest Medicines Limited, 2021 Earnings Call, Mar 29, 2022
CI
03/28Everest Medicines Announces Financial Results for Full Year Ended December 31, 2021
PR
03/28Everest Medicines Limited Appoints Leah Liu as Joint Company Secretary
CI
03/21Calliditas Therapeutics AB - Updated regulatory plans for NEFECON in China
AQ
03/18Calliditas Therapeutics Says Partner Everest Medicines Plans to File Nefecon NDA in Chi..
MT
More news
Analyst Recommendations on EVEREST MEDICINES LIMITED
More recommendations
Financials
Sales 2022 193 M 28,6 M 28,6 M
Net income 2022 -1 095 M -162 M -162 M
Net cash 2022 873 M 129 M 129 M
P/E ratio 2022 -5,07x
Yield 2022 -
Capitalization 5 573 M 825 M 825 M
EV / Sales 2022 24,4x
EV / Sales 2023 2,97x
Nbr of Employees 405
Free-Float 100%
Chart EVEREST MEDICINES LIMITED
Duration : Period :
Everest Medicines Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EVEREST MEDICINES LIMITED
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 18,76 CNY
Average target price 34,67 CNY
Spread / Average Target 84,8%
EPS Revisions
Managers and Directors
Kerry Levan Blanchard Chief Executive Officer & Executive Director
Ian Ying Woo President, CFO & Executive Director
Wei Fu Executive Chairman
Xinhui Hu Chief Technology Officer
Jennifer Yang Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
EVEREST MEDICINES LIMITED-35.49%850
CSL LIMITED-6.06%91 946
SAMSUNG BIOLOGICS CO.,LTD.-11.85%44 385
BIOGEN INC.-18.43%28 662
WUXI BIOLOGICS (CAYMAN) INC.-42.79%28 457
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.-26.31%22 129